Cross‐Neutralizing and Broadly Neutralizing Human Antibodies Against Nonenveloped Viruses
Abstract
Neutralizing antibodies (NAbs) play a central role in antiviral protection and are increasingly considered for prophylactic or therapeutic use, particularly against viruses lacking effective antiviral treatments. While research has predominantly focused on NAbs targeting the envelope proteins of enveloped viruses, nonenveloped viruses remain major human pathogens for which broad antibody responses are less well characterized. Recent work has identified several cross‐ and broadly neutralizing antibodies generated during human infection with nonenveloped viruses, revealing different mechanisms of action and new structural vulnerabilities. This review provides an overview of these NAbs, summarizes their mechanisms of action when these have been identified, and highlights recent advances relevant to antiviral antibody development and vaccine research.
Related
- Structure-guided vaccination elicits broadly neutralizing antibodies targeting the HIV-1 silent face
- Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies
- Vaccination elicits HIV broadly neutralizing antibodies in primates
- N1 neuraminidase monoclonal antibodies 2H08 and 3H03 have decreased binding and inhibition properties against H1N1 influenza viruses circulating after 2018
- Computational design of potent, broadly neutralizing anti-Nipah virus and Hendra virus miniproteins
BibTeX
@article{marchand2026crossneutralizing,
title = {{Cross‐Neutralizing and Broadly Neutralizing Human Antibodies Against Nonenveloped Viruses}},
author = {Sarah Marchand and Samy Taouli and Dorian Mcilroy},
journal = {European Journal of Immunology},
year = {2026},
month = oct,
doi = {10.1002/eji.70290},
url = {https://hal.science/hal-05797113v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Cross‐Neutralizing and Broadly Neutralizing Human Antibodies Against Nonenveloped Viruses
AU - Sarah Marchand
AU - Samy Taouli
AU - Dorian Mcilroy
PY - 2026
DA - 2026/10/08
JO - European Journal of Immunology
DO - 10.1002/eji.70290
UR - https://hal.science/hal-05797113v1
AB - Neutralizing antibodies (NAbs) play a central role in antiviral protection and are increasingly considered for prophylactic or therapeutic use, particularly against viruses lacking effective antiviral treatments. While research has predominantly focused on NAbs targeting the envelope proteins of enveloped viruses, nonenveloped viruses remain major human pathogens for which broad antibody responses are less well characterized. Recent work has identified several cross‐ and broadly neutralizing antibodies generated during human infection with nonenveloped viruses, revealing different mechanisms of action and new structural vulnerabilities. This review provides an overview of these NAbs, summarizes their mechanisms of action when these have been identified, and highlights recent advances relevant to antiviral antibody development and vaccine research.
SN - 0014-2980
SN - 1521-4141
ER -